Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotech company focused on developing prophylactic therapeutics for bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, the company is advancing a pipeline of monoclonal and bispecific antibody-based therapeutics aimed at transforming the treatment landscape for patients with high unmet needs. Hemab's strategic guidance, Hemab 1-2-5, outlines the development of 5 clinical assets by 2025 to address conditions such as Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, and other serious disorders. Founded in 2019, the company attracted a substantial $135.00M Series B investment on 21 February 2023, with notable participation from investors including Novo Holdings, Maj Invest Private Equity, RA Capital Management, HealthCap, Invus, Access Biotechnology, Deep Track Capital, Rock Springs Capital, and Avoro Ventures. For more information, visit hemab.com. This innovative firm is making significant strides in the biotechnology, life sciences, and pharmaceutical sectors.